These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 75498)

  • 1. Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma.
    Bellet RE; Catalano RB; Mastrangelo MJ; Berd D
    Med Pediatr Oncol; 1978; 4(1):11-5. PubMed ID: 75498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of 5-azacytidine in sarcomas of bone.
    Srinivasan U; Reaman GH; Poplack DG; Glaubiger DL; LeVine AS
    Am J Clin Oncol; 1982 Aug; 5(4):411-5. PubMed ID: 6180626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and a nitrosourea.
    Bellet RE; Catalano RB; Mastrangelo MJ; Berd D
    Cancer Treat Rep; 1978 Dec; 62(12):2095-9. PubMed ID: 751717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice weekly 5-azacytidine infusion in dissmeinated metastatic cancer: a phase II study.
    Vélez-Garcia E; Vogler WR; Bartolucci AA; Arkun SN
    Cancer Treat Rep; 1977 Dec; 61(9):1675-7. PubMed ID: 74283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816).
    Bellet RE; Mastrangelo MJ; Engstrom PF; Strawitz JG; Weiss AJ; Yarbro JW
    Cancer Chemother Rep; 1974; 58(2):217-22. PubMed ID: 4133839
    [No Abstract]   [Full Text] [Related]  

  • 6. DTIC (NSC-45388) studies in the southwest oncology group.
    Costanzi JJ
    Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
    Samson MK; Baker LH; Talley RW; Fraile RJ; McDonald B
    Cancer Treat Rep; 1978 Aug; 62(8):1223-5. PubMed ID: 356980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816).
    Lomen PL; Khilanani P; Kessel D
    Neoplasma; 1980; 27(1):101-6. PubMed ID: 6154898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of 5-azacytidine (NSC-102816).
    Shnider BI; Baig M; Colsky J
    J Clin Pharmacol; 1976 Apr; 16(4):205-12. PubMed ID: 57124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
    Bellett RE; Mastrangelo MJ; Laucius JF; Bodurtha AJ
    Cancer Treat Rep; 1976 May; 60(5):595-600. PubMed ID: 791478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 5-azacytidine (NSC-102816) with CCNU (NSC-79037) in the treatment of patients with breast cancer and evaluation of the subsequent use of cyclophosphamide (NSC-26271).
    Cunningham TJ; Nemoto T; Rosner D; Knight E; Taylor S; Rosenbaum C; Horton J; Dao T
    Cancer Chemother Rep; 1974; 58(5 Pt 1):677-81. PubMed ID: 4138966
    [No Abstract]   [Full Text] [Related]  

  • 12. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
    Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P
    Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
    Johnson RO; Metter G; Wilson W; Hill G; Krementz E
    Cancer Treat Rep; 1976 Feb; 60(2):183-7. PubMed ID: 769971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
    Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
    Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DTIC (NSC-45388) in malignant melanoma: a perspective.
    Comis RL
    Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
    [No Abstract]   [Full Text] [Related]  

  • 16. Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study.
    Gundersen S
    Cancer Treat Rep; 1987 Nov; 71(11):997-9. PubMed ID: 3677119
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I study of twice weekly 5-azacytidine (NSC-102816).
    Vogler WR; Arkun S; Velez-Garcia E
    Cancer Chemother Rep; 1974; 58(6):895-9. PubMed ID: 4141280
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of refractory adult acute nonlymphoblastic leukemia with subcutaneous 5-azacytidine.
    Armitage JO; Burns CP
    Cancer Treat Rep; 1977 Dec; 61(9):1721-3. PubMed ID: 74285
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma.
    Samson MK; Baker LH; Izbicki RM; Ratanatharathorn V
    Cancer Treat Rep; 1976 Sep; 60(9):1369-71. PubMed ID: 65223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
    Middleton MR; Grob JJ; Aaronson N; Fierlbeck G; Tilgen W; Seiter S; Gore M; Aamdal S; Cebon J; Coates A; Dreno B; Henz M; Schadendorf D; Kapp A; Weiss J; Fraass U; Statkevich P; Muller M; Thatcher N
    J Clin Oncol; 2000 Jan; 18(1):158-66. PubMed ID: 10623706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.